In addition, platelet-derived growth factor receptor-beta (PDGFR-β), which is enriched in EVs released by melanoma cells resistant to BRAF inhibitor, PLX4720, can be transferred to recipient melanoma cells, resulting in a dose-dependent activation of PI3K/AKT signaling and escape from BRAF inhibition [104]. Here, PDGFRB is linked to melanoma.